A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Vertex Pharmaceuticals am 52-Wochenhoch – Studie für Stammzellentherapie gegen Diabetes-Typ-1 wird fortgesetzt!
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
Vertex buys diabetes cell therapy rival ViaCyte for $320m | pharmaphorum
New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials
Stem Cell-Based 'Cure' for Type 1 Diabetes
Vertex Pharmaceuticals announces they have acquired ViaCyte | JDRF Canada
FDA orders stop to Vertex diabetes study - Boston Business Journal
AKTIONÄR-Tipp Vertex: Übernahme – Aktie auf Jahreshoch - DER AKTIONÄR
FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
Vertex (VRTX) Stock Falls After FDA Pauses Diabetes Study in Surprise Move - Bloomberg
Deal Boosts Gene-Editing Technology Aiming to Cure Type 1 Diabetes
Vertex (VRTX) Seeks Human Trials of Therapies for Cystic Fibrosis, Diabetes - Bloomberg
Vertex präsentiert neue Daten aus der klinischen Phase-1/2-Studie zu VX-880 bei den 82. Scientific Sessions der American Diabetes Association | Business Wire
Vertex snaps up diabetes stem cell rival | Nature Biotechnology
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Vertex to pay CRISPR $100m to use gene editing tech for diabetes therapy
Stem-Cell Therapy for Type 1 Diabetes Reduced Patient's Insulin Needs by 91%
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex to acquire ViaCyte, targeting type 1 diabetes
Vertex signs licence deal with CRISPR for diabetes therapies
Type 1 Diabetes Cures in Spotlight with Vertex Deal
Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes - MedCity News
Vertex: Impressive early results for potentially curative diabetes cell therapy
